PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.13
Positive D/E while AGEN shows negative equity. John Neff would examine our competitive advantages in a challenging market.
2.00
Similar net debt to AGEN's 2.06. Guy Spier would examine if industry leverage norms make sense for both companies.
No Data
No Data available this quarter, please select a different quarter.
2.63
Current ratio exceeding 1.5x AGEN's 0.81. Charlie Munger would verify if this advantage translates to better supplier terms.
No Data
No Data available this quarter, please select a different quarter.